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Summary. Recent advances have been made in the 
cellular and molecular mechanisms involved in 
monostotic and polyostotic fibrous dysplasia, a rare 
nonmalignant disease causing bone deformations and 
fractures. The molecular basis of fibrous dysplasia has 
been clarified when mutations affecting the stimulatory 
a subunit of G protein (Gs) have been found in 
dysplastic bone lesions. The histological analysis of 
dysplastic lesions revealed that the mutations in G s a  
caused abnormalities in cells of the osteoblastic lineage 
and therefore in the bone matrix. Further in vitro 
analyses of bone cells from mutant dysplastic bone 
lesions revealed that the abnormal deposition of 
immature bone matrix in fibrous dysplasia results from 
decreased differentiation and increased proliferation of 
osteoblastic cells. Finally, the signaling pathway 
involved in these osteoblastic abnormalities has been 
identified. It is now apparent that the constitutive 
elevation in cAMP leve1 induced by the Gsa mutations 
leads to alterations in the expression of several target 
genes whose promoters contain cAMP-responsive 
elements, such as c-fos, c-jun, 11-6 and 11-11. This in turn 
affects the transcription and expression of downstream 
genes and results in the alterations of osteoblast 
recruitment and function in dysplastic bone lesions. 
These mechanisms provide a cellular and molecular 
basis for the alterations in bone cells and bone matrix in 
fibrous dysplasia. 
Key words: Osteoblasts, Bone formation, Fibrous 
dysplasia, McCune-Albright syndrome, Gsa  mutations 
Introduction 
During the last decade, significant advances have 
been made in the understanding of cellular and 
molecular mechanisms involved in the etiology of 
fibrous dysplasia, a rare nonmalignant bone disease. 
This has been made possible by the discovery of genetic 
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mutations expressed in dysplasic cells, and by the 
identification at the tissue and cellular levels of the 
resulting cellular abnormalities. In this review, 1 will 
surnmarize the pathophysiological mechanisms 
responsible for the bone disorders in fibrous dysplasia, 
based on results obtained in my and other laboratories. 
Pathology and histology of fibrous dysplasia 
Fibrous dysplasia is a benign disease characterized 
by foca1 bone lesions and occuring sporadically. Most 
patients (70%) present with a single area of dysplasia 
(monocystic fibrous dysplasia), but some have multiple 
areas affected (polyostotic fibrous dysplasia). The 
lesions may be asymptomatic or be present with local 
pain, deformities, fractures and growth abnormalities 
during childhood and at puberty (McCune, 1936; 
Albright et al., 1937; Harris et al., 1962). Several parts 
of the skeleton may be affected, including femur, tibia, 
humerus, pelvis, skull and ribs (Harris et al., 1962; 
Cohen and Howell, 1999). In a small number of cases, 
fibrous dysplastic lesions may degenerate into malignant 
tumors, osteosarcoma and chondrosarcoma (Yabut et al., 
1988). A minority (about 3%) of polyostotic patients 
with McCune-Albright syndrome present skin 
pigmentation called "café-au-lait" lesions (McCune, 
1936; Albright et al., 1937), associated with multiple 
endocrinopathies. This  includes sexual precocity, 
hyperthyroidism, growth hormone excess and 
acromegaly, hyperprolactinemia and adrenal hyperplasia 
resulting from autonomous hypersecretion of hormones. 
Radiologically, the lesions present in the metaphysis and 
diaphysis of long bones appear cystic and may expand 
from the marrow cavity to the surrounding cortex. 
Histologically, lesions of fibrous dysplasia have variable 
characteristics depending on their location (Grabias et 
al., 1977; Shenker et al., 1994; Marie et al., 1997; Marie, 
1999a; Riminucci et al., 1999). Craniofacial lesions are 
often present as dense fibrous bone tissue (Riminucci et 
al., 1999). In long bone, dysplast ic  lesions are 
characterized by an accumulation of disconnected 
trabecular, poorly mineralized bone matrix which is 
mixed with the normal lamellar bone (Shenker et al., 
1994; Marie et al., 1997; Marie, 1999a; Riminucci et al., 
1999) (Fig. 1A). The more severe lesions present with 
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irnmature woven bone which is not replaced by mature 
lamellar bone (Marie et al., 1997; Riminucci et al., 
1999). The lack of connectivity and the immature nature 
of the bone formed results in decreased mechanical 
properties of the bone, leading to deformations and 
fractures. 
Osteoblast abnormalitles in flbrous dysplasia 
The histological analysis of dysplastic lesions 
suggest the existente of abnormalities in the formation 
of osteoprogenitor cells (Marie et al., 1997; Marie, 
1999a; Riminucci et al., 1999). Indeed, the number of 
immature osteoblasts is low. Moreover, cells located 
along the bone surface are not oriented and elongated, 
and are distinct from normal cuboidal mature osteoblasts 
(Fig. lA,B). The marrow cavity is filled with elongated, 
immature, alkaline phosphatase-positive cells, and this 
cellular invasion does not allow the normal development 
of hematopoietic and adipogenic populations (Fig. 1C). 
These histological characteristics indicate that the pre- 
osteoblastic population is  increased whereas the 
population of mature cells is  decreased. Defective 
osteoblast differentiation is  also evidenced by the 
abnormal collagen organization in the immature bone. 
The collagen fibers are not parallelly oriented, a 
characteristic of immature woven bone. The collagen 
fibers sometimes appear perpendicular to the bone 
surface, showing a comb-like structure (Fig. 1A). These 
abnormalities found in both monostotic and polyostotic 
lesions reflect a disorganization of collagen fibers 
synthesized by dysplastic cells (Marie et al., 1997; 
Riminucci et al., 1999). In addition to the abnormal 
formation and orientation of collagen, non-collagenous 
protein synthesis is affected. Osteonectin leve1 is  
increased, whereas osteopontin and bone sialoprotein are 
decreased in dysplastic bone, reflecting the immature 
composition of the matrix (Marie et al., 1997; Riminucci 
et al., 1999; Sakamoto et al., 1999). The reduced content 
in some of these bone proteins in the matrix may reduce 
the adherence of osteoblasts, leading to cell retraction 
and disorientation (Riminucci et al., 1999). As a result of 
the disorganized immature bone matrix, osteocytes 
arising from dysplastic osteoblasts are more numerous 
than normal, and are located within large lacunae. They 
also do not form a well organized network through 
intercellular extensions present in the canaliculi within 
the bone matrix (Fig. 1B). In addition to these alterations 
of the osteoblast lineage, there are zones of active bone 
resorption in dysplastic bone that are caracterized by the 
presence of multiple osteoclasts actively resorbing the 
mineralized matrix and forming local lytic areas (Fig. 
1B). Some of the histological characteristics found in 
fibrous dysplasia (marrow invasion, hyper-resorption, 
immature bone, lytic areas) are also found in severe 
hyperparathyroidism and other cases of high turnover of 
bone (Rasmussen and Bordier, 1974). 
Cellular basls of fibrous dysplasia 
The availability and development of bone cell 
cultures obtained from dysplastic lesions allowed us to 
identify the cellular abnormalities in osteoblasts in both 
monostotic and polyostotic fibrous dysplasia. We found 
that dysplastic cells show an increased proliferation rate 
associated with elevated intracellular cyclic AMP 
Flg. 1 stological abnormalities induced by Gsa mutations in polyostotic fibrous dysplasia in the McCune-Albright syndrome (A, C) 
and in monostotic fibrous dysplasia (8). Bone lesions are characterized by immature fibrotic bone (F), irregular osteoid (o) and 
disorganized collagen which presents a comb-like structure (A: arrows). Mature osteoblasts are rare and numerous osteocytes (B: 
Ocy) are found in large lacunae within the immature bone. Bone resorption by osteoclasts (B: Ocl) is locally increased. The marrow 
(M) space is invaded by immature osteoprogenitor cells wihich present alkaline phosphatase activity (C: arrows). A, B, x 125; C, x 250 
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(cAMP) levels (Marie et al., 1997). Osteoblastic cells 
isolated from the more severe bone lesions, composed of 
immature bone matrix, show a less differentiated 
phenotype and increased proliferative rate compared to 
cells from the less affected lesions composed of a 
mixture of mature and immature bone matrix. This 
indicates that the increased cell proliferation is 
associated with the less differentiated osteoblast 
phenotype in the dysplastic lesions. In addition to the 
increased cell proliferation, dysplastic cells show 
decreased differentiation, as evidenced by the alteration 
of osteocalcin mRNA expression and protein synthesis 
(Marie et al., 1997; Sakamoto et al., 1999; Hopyan et al., 
1999). However, dysplastic cells respond normally to 
1,25-dihydroxyvitamin D which enhances osteocalcin 
expression in osteoblasts (Marie et al., 1997). The 
expression of Runx21Cbfa1, a master transcription factor 
known to stimulate osteocalcin expression (Karsenty, 
2000), was found to be increased in dysplastic bone cells 
(Sakamoto et al., 1999). One possible explanation for the 
increased Runx2lCbfal expression with regard to the 
reduced osteocalcin expression is that dysplastic cells 
express high levels of Msx2, a transcription factor that is 
expressed early during osteoblast differentiation and that 
inhibits osteocalcin expression (Newberry et al., 1997). 
The concomittant decrease in cell differentiation and 
increased proliferation of pre-osteoblastic cells in 
dysplastic lesions lead to a rapid deposition of an 
immature, poorly organised woven bone characteristic of 
the bone lesion at the histological leve1 (Marie et al., 
1997; Riminucci et al., 1999). 
Molecular basis of fibrous dysplasia 
The molecular basis of fibrous dysplasia has been 
clarified when mutations affecting the stimulatory a sub- 
unit of G protein (Gs) have been found in dysplastic 
bone lesions. In the cell membrane, adenylate cyclase is 
coupled to hormonal receptors by a G protein which 
binds ATP (Fig. 2). This protein is composed of a ,  13 and 
y subunits. When inactivated, the a-subunit binds GTP. 
When a ligand binds to the receptor, the a-subunit is 
released from the remaining By protein complex. This 
process is reversed through GTP hydrolysis by the 
intrinsic GTPase activity of the Gsa protein (Spiegel et 
al., 1992). The a chain of the G protein binds and 
hydrolyses GTP, and thereby activates adenylate cyclase 
that produces cAMP (Fig. 2). Mutations in the Gsa have 
been initially identified in multiple endocrinopathies 
(Landis et al., 1989; Lyons et al., 1990). In these 
pathologies, a constitutive activation of Gsa leads to 
accumulation of cAMP in endocrine tissues, leading to 
increased cell proliferation and hormonal secretion 
(Klibanski, 1990; Landis et al., 1990; Spada et al., 
1990). This was found in autonomous thyroid and 
pituitary tumors, as a result of somatic mutations of Gsa 
(arginin20lcystein or glutamin227leucin). These 
activating mutations inhibit the GTPase activity of Gsa, 
resulting in increased adenylate activity and increased 
cAMP levels (Spiegel et al., 1993; Spiegel, 2000) (Fig. 
2). In the McCune-Albright syndrome, activating 
mutations were found in exon 8 of the Gsa gene in 
patients with endocrinopathies (Weinstein et al., 1991; 
Ringel et al., 1996). In this syndrome, somatic mutations 
of G s a  were found at variable levels in several 
endocrine or non endocrine tissues, leading to a mosaic 
distribution of the somatic mutation early during 
embryogenesis, and resulting in multiple and variable 
endocrinopathies later on (Cuttler et al., 1989; Shenker 
et al., 1993, 1994; Malchoff et al., 1994; Levine, 1999). 
The mutations consist of the substitution of cystein 
(R201C) or histidin (R201H) by arginin at position 201 
in Gsa. Another mutation such as R201G (Shenker et al, 
1995; Candeliere et al., 1997; Riminucci et al., 1997) or 
mutations which do not affect Gsa have also been found 
in patients with fibrous dysplasia (Gessl et al., 1994). 
However, fibrous dysplasia is not associated with 
aberrent chromosomic recombinations (Da1 Cin et al., 
2000). 
Mutations of Gsa have been found by RT-PCR 
analysis in dysplastic bone lesions (Shenker et al., 1995; 
Candeliere et al., 1997; Riminucci et al., 1997). The 
culture of osteoblastic cells isolated from dysplastic 
bone lesions allowed us to show the expression of 
R201C and R201H mutations in dysplastic bone cells 
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Fig. 2. Schematic representation of the effects of Gsa mutation 
on adenylate cyclase activity. Adenylate cyclase is coupled to 
hormonal receptors by the Gsa protein. When the receptor is 
activated, the a chain of the protein binds and hydrolyses GTP 
to GDP, thereby activating adenylate cyclase which leads to 
cAMP production. Gsa-activating mutations (Gsa*) inhibit the 
GTPase activity. resulting in  increased adenylate cyclase 
act iv i ty and increased cAMP accumulation. This leads to 
activation of proteine kinase A and phosphorylation of a number 
of target rnolecules. 
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(Shenker et al., 1995). These mutations are expressed in 
both monostotic and polyostotic fibrous dysplasia 
(Shenker et al., 1995; Alman et al., 1996) and represent 
the molecular basis of the cellular abnormalities in the 
two types of fibrous dysplasia. Interestingly, further 
analyses indicated that not al1 bone cells within the 
dysplastic lesions express such mutations (Riminucci et 
al., 1997). This mosaic distribution allows cell survival 
because the mutations are lethal (Happle, 1986). It  is 
therefore believed that Gsa  mutations which appear 
early during embryogenesis induce the generalized 
abnormalities found in the McCune-Albright syndrome, 
whereas the somatic mutations appearing later in life 
induce more restricted pathologies such as thyroid and 
pituitary adenomas, and monostotic fibrous dysplastic 
lesions. Thus, the endocrine and skeletal lesions 
associated with these mutations reflect a variable 
phenotypic expression of the mutations resulting from a 
somatic mosaicism of a same molecular alteration 
(Ringel et al., 1996; Spiegel, 1996; Cohen and Howell, 
1999). In dysplastic lesions, G s a  mutations are 
expressed in osteoprogenitor cells present in the marrow 
stroma (Marie et al., 1997; Bianco et al., 2000). The 
frequence of expression of mutations is higher in 
polyostotic than in monostotic fibrous dysplasia (Stanton 
et al., 1999). In terms of functional activity, dysplastic 
cells from monostotic and polyostotic lesions are able to 
be osteogenic in vitro in the presence of glucocorticoids 
which stimulate osteoblastic cell differentiation. 
However, mutated dysplastic cells are not osteogenic in 
vivo, probably because of the lethality induced by the 
mutation. Only mixed mutated and non mutated cells 
reconstituting the natural mosaic are able to form 
dysplastic lesions in vivo (Bianco et al., 1998). This 
indicates that Gsa  mutations are responsible for the 
formation of dysplastic bone lesions, and that the 
presence of mutated and nonmutated cells is required for 
the development of the lesion (Bianco et al., 1998). 
Molecular mechanisms of fibrous dysplasia 
The formation of dysplastic bone lesions resulting 
from Gsa mutations involves severa1 mechanisms. In 
theory, activating mutations of Gsa should induce 
stimulation of adenylate cyclase and increased cAMP 
accumulation (Fig. 2). Accordingly, we found that Gsa 
mutations induce a constitutive accumulation of cAMP 
in osteoblastic cells in the McCune-Albright syndrome 
(Marie et al., 1997) and this was confirmed by other 
groups (Candeliere et al., 1997; Bianco et al., 1998). The 
downstream events leading to the abnormal cellular 
phenotype in osteoblastic cells are linked to cAMP 
signaling. The signaling pathways induced by cAMP are 
known to tightly control gene expression (Borrelli et al., 
1992). cAMP accumulation activates protein kinase A 
which then phosphorylates transcription factors that are 
members of the cAMP-response-element-binding- 
protein (CREB) family. This leads to binding of these 
proteins to DNA domains called cAMP-responsive 
element (or CRE) in the promoter of target genes 
(Montminy et al., 1990). This pathway controls the 
expression of multiple genes in several endocrine and 
nonendocrine tissues. For example, in pituitary cells, the 
increased activity of PKA induced by Gsa-activating 
mutations stimulate the promotor activity of prolactin 
and growth hormone (Tian et al., 1994; Gaiddon et al., 
1995), leading to endocrinopathies associated with the 
mutation. In osteoblastic cells, a rise in cAMP induced 
by Gsa mutations also induce multiple effects (Fig. 3). 
One of the more rapid effects is cell retraction which is 
observed in dysplastic cells (Riminucci et al., 1997). 
This may be explained by the rapid disassembling effect 
of cAMP on cytoskeletal proteins leading to cell 
retraction (Lomri and Marie, 1990). The rise in cAMP in 
mutated dysplastic cells may also be responsible for the 
decreased expression of bone matrix proteins, such as 
osteopontin (Noda and Rodan, 1989) whose promoter 
contains cAMP-responsive elements (Kopp et al., 1989; 
Kerr et al., 1993). The rise in cAMP is also likely to be 
involved in the increased bone resorption found in 
dysplastic lytic lesions. Such local stimulation of bone 
resorption is found in severe cases of 
hyperparathyroidism in which high levels of parathyroid 
hormone induces elevated intracellular cAMP levels in 
osteoblasts (Lomri and Marie, 1990) and results in 
increased osteoclastic bone resorption by increasing 
bone resorbing cytokines (see below). 
The elevation in cAMP induced by the Gsa is a an 
important mechanism leading to bone cell abnormalities 
Gsa* + c fos 
t -  + c Jun -+ AP-1 
Alteration of 
Bone Matrix 
Pro teins 
Lesions 
Fig. 3. Molecular rnechanisrns involved in fibrous dysplasia. The 
rnutations in Gsa (Gsa*) result in increased intracellular cAMP 
levels that rnodulate the expression of several genes whose 
promoter contains a cAMP-responsive elernent (CRE). This 
pathway leads to abnormal production of bone rnatrix proteins 
and to increased c- fos express ion,  leading to  abnormal 
recruitrnent and function of osteoblastic cells, and to abnormal 
bone rnatrix production. The cAMP overproduction induced by 
the mutation also leads to increased production of interleukin-6 
and -1 1 (11-6, 11-1 1) which in turn stimulate osteoclastic bone 
resorption. These rnolecular mechanisms induced by the Gsa 
rnutations result in the forrnation of dysplastic bone lesions. 
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in fibrous dysplasia (Fig. 3). One mechanism involves c- 
fos, a protein that forms heterodimers with proteins of 
the jun family, forming a complex that binds to specific 
sequences in the promoter of several genes (Angel and 
Karin, 1991). The c-fos promoter contains a cAMP- 
reponsive element (Sassone-Corsi et al., 1988), and is 
therefore a potential target for Gsa mutations in fibrous 
dysplasia. Indeed, Gsa-activating mutations induce c-fos 
overexpression in vitro (Sassone-Corsi et al., 1988). In 
endocrine cells, the Gsa-induced stimulation of c-fos 
transcription involves multiple sequences such as CRE 
and the serum responsive element SRE (Gaiddon et al., 
1994). In bone, Gsa mutations increase c-fos expression 
and c-jun, which acts by binding c-fos and forms the 
AP-1 heterodimer complex. In endocrine cells, 
mutations of Gsa increase c-jun and Jun B expression 
(Gaiddon et al., 1994). Histological analysis 
demonstrated an increased expression of both c-fos and 
c-jun in dysplastic lesions (Sakamoto et al., 1999) which 
may in turn induce abnormal expression of genes 
controlled by AP-1 (Angel and Karin, 1991; Sassone- 
Corsi, 1995). Members of the AP-1 family are important 
factors regulating bone formation. For example, deletion 
or overexpression of c-fos in transgenic mice induces 
severe bone abnormalities (Grigoriadis et al., 1995). c- 
fos over-expression in mice results in increased bone 
formation, with characteristics similar to those found in 
dysplastic bone lesions (Grigoriadis et al., 1995). In 
vitro, AP-1 controls genes that are involved in osteoblast 
differentiation, and c-fos expression modulates the 
expression of osteoblast genes such as osteocalcin and 
osteopontin whose promoter contains AP-1 sites (Lian et 
al., 1991). In situ hybridization and immunohisto- 
chemical analyses showed that c-fos mRNA and protein 
levels are high in bone lesions of dysplastic patients with 
Gsa mutations (Candeliere et al., 1995). Thus, c-fos 
overexpression in fibrous dysplasia may be involved in 
the molecular mechanisms leading to the bone lesions. c- 
fos is often overexpressed in human osteosarcomas (Wu 
et al., 1990). Moreover, experimental studies showed 
that c-fos can induce oncogenic transformation in mouse 
osteoblasts (Grigoriadis et al., 1993, 1995). Thus, c-fos 
overexpression may be part of the mechanisms leading 
to tumor development in some cases of fibrous dysplasia 
(Yabut et al., 1988). Several mechanisms can be evoked 
to explain how c-fos overexpression can induce the 
cellular abnormalities found in dysplastic bone lesions. 
The increased c-fos protein by cAMP may induce cells 
to enter into the G1 phase of the cellular cycle 
(Herschman, 1991). This is consistent with the finding 
that c-fos is expressed by immature osteoblasts and 
controls osteoblast proliferation and differentiation (Lian 
et al., 1991; Machwate et al., 1995a,b). It seems 
therefore possible that the increased osteoblastic cell 
proliferation and the abnormal osteoblast differentation 
observed in fibrous dysplasia results in part from the 
increased expression of c-fos and other members of the 
AP-1 family. 
As discussed above, localized lytic lesions are found 
in dysplastic lesions. At least two cytokines may be 
responsible for this local increase in bone resorption in 
fibrous dysplasia. Osteoprogenitor cells bearing the 
R201H Gsa mutation show a constitutive increase in 
interleukin-6 (11-6) production (Yamamoto et al., 1996). 
In addition, less differentiated cells present in the bone 
lesions produce more IL-6 levels (Stanton et al., 1999). 
Inhibition of cAMP levels in mutant cells reduce 11-6 
production, suggesting that the Gsa mutation-induced 
increased cAMP levels results in 11-6 overexpression 
(Yamamoto et al., 1996). This is consistent with the 
finding that transfection of the mutated G s a  in 
osteoblastic cells induces 11-6 production (Motomura et 
al., 1998). The 11-6 promoter presents cAMP-responsive 
elements, as well as AP-1 and NF-KB sites (Kishimoto, 
1989). The Gsa mutation increases binding of AP-1, 
nuclear factor NF-IL-6, NF-KB and CREB to the IL-6 
promoter, which can thus account for the increased 
expression of this cytokine in dysplastic osteoblasts 
(Motomura et al., 1998). The implication of 11-6 in the 
increased bone resorption in dysplastic cystic lesions 
(Yamamoto et al., 1996) is supported by the finding that, 
in other bone diseases characterized by increased bone 
resorption such as postmenopausal osteoporosis and 
Paget's disease, increased 11-6 stimulates osteoclast 
differentiation and bone resorption (Jilka et al., 1992; 
Roodman, 1992). Interestingly, glucocorticoids were 
found to decrease 11-6 production by dysplastic cells and 
to reduce bone resorption, which may be of potential 
therapeutic interest in the treatment of fibrous dysplasia 
(Stanton et al., 1999). 11-11 production was also found to 
be increased in mutated dysplastic cells (Yamamoto et 
al., 1996), suggesting that this bone resorbing cytokine 
may also be involved in the lytic lesions in this 
syndrome. Recent data indicate that local molecules 
produced by stromal cells and osteoblasts play a major 
role in osteoclast differentiation and bone resorption 
(Marie et al., 2000; Hofbauer et al., 2000). Such 
molecules are involved in the increased bone resorption 
induced by several local factors such as IL-6 and 11-11 
(Hofbauer et al., 2000). It is thus possible that these 
molecules may be the final step of IL-6- and 11-11- 
induced bone resorption induced by Gsa mutations in 
fibrous dysplasia. 
The cellular alterations observed in fibrous dysplasia 
may involve other mechanisms. Two studies reported an 
increased leve1 for estrogen expression in osteoblasts in 
both monostotic fibrous dysplasia and McCune-Albright 
syndrome (Kaplan et al., 1988; Pensler et al., 1990). This 
was not linked to the endocrine status of the subjects and 
could thus reflect abnormal regulation of these receptors 
(Pensler et al., 1990). This abnormality may contribute 
to the bone pathology in this syndrome because 
estrogens stimulate the proliferation of osteoblastic cells 
in part by increasing the expression of local growth 
factors such as IGF-1 and TGF-B (Rickard et al., 1999) 
which are important factors controling osteogenesis 
(Marie, 1999b). It is not known, however, whether the 
expression of these growth factors is increased locally in 
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fibrous dysplasia. Finally, a rise in the expression of the 
parathyroid hormone related peptide (PTHrP) has been 
recently reported in osteoblastic cells of patients with the 
McCune-Albright syndrome. A treatment with 1,25- 
dihydroxy-vitamin D3 can reduce the production of 
PTHrP in vitro as well as bone markers in this disease. It 
is thus possible that a local increase in the expression of 
PTHrP, which acts on bone cells in a similar way to 
PTH, could contribute to the bone cell alterations in the 
McCune Albright syndrome (Fraser et al., 2000). 
Conclusion 
The discovery that Gsa  mutations are expressed in 
dysplastic bone cells provided a basis for the cellular and 
molecular mechanisms involved in the osteoblast 
alterations observed in fibrous dysplasia. I t  is now 
apparent that the abnormal osteoblastic cell proliferation 
and differentiation obsewed in fibrous dysplasia result 
f rom increased cAMP accumulation, leading to 
alteration in the expression of target genes including c- 
fos, c-jun, 11-6, 11-11, which in turn modulate the 
transcription and expression of downstream genes and 
result in the alterations of osteoblast and osteoclast 
recruitment and function in the dysplastic bone lesions. 
These pathways provide a cellular and molecular basis 
for the bone alterations in fibrous dysplasia. Further 
analysis of the molecular pathways activated by the Gsa  
mutations in dysplastic bone cells may lead to the 
identification of target genes for cellular therapies and 
allow us in the future to develop a therapeutic approach 
of the skeletal alterations in fibrous dysplasia. 
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